No Data
On December 20, PHARMARON (03759.HK) spent 13.7375 million Hong Kong dollars to repurchase 1 million shares.
On December 20, Gelonghui reported that PHARMARON (03759.HK) announced the repurchase of 1 million shares at a cost of 13.7375 million Hong Kong dollars on December 20, 2024, with a repurchase price ranging from 13.58 to 13.94 Hong Kong dollars per share.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
On December 19, PHARMARON (03759.HK) spent 5.4567 million Hong Kong dollars to repurchase 0.4 million shares.
On December 19, Gelonghui announced that PHARMARON (03759.HK) spent HKD 5.4567 million to repurchase 0.4 million shares on December 19, 2024, with a repurchase price of HKD 13.48-13.8 per share.
On December 18, PHARMARON (03759.HK) spent 5.5632 million HKD to repurchase 0.4 million shares.
Glory Financial reported on December 18 that PHARMARON (03759.HK) announced it will spend 5.5632 million Hong Kong dollars to repurchase 0.4 million shares on December 18, 2024, with a buyback price of 13.76-14 Hong Kong dollars per share.
On December 17, PHARMARON (03759.HK) spent 2.763 million Hong Kong dollars to repurchase 0.2 million shares.
Gelonghui, December 17, PHARMARON (03759.HK) announced that on December 17, 2024, it spent 2.763 million Hong Kong dollars to repurchase 0.2 million shares, with a repurchase price of 13.7-13.98 Hong Kong dollars per share.
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Expand
No Data
102884128 : getting disappointed with this counter. every day drop.